Alteogen Licenses Out ALT-B4 Human Hyaluronidase Technology... Worth Up to $3.223 Billion (Approx. 4.4165 Trillion Won)
Alteogen has signed a large-scale technology export contract based on its proprietary human hyaluronidase technology 'ALT-B4'. If the counterparty exercises all granted options and the development and commercialization of multiple products proceed as planned, the total contract value the company cou

Alteogen has signed a large-scale technology export contract based on its proprietary human hyaluronidase technology 'ALT-B4'. If the counterparty exercises all granted options and the development and commercialization of multiple products proceed as planned, the total contract value the company could receive reaches up to $3.223 billion (approximately 4.4165 trillion won). Royalties from product sales will be paid separately from this amount.
■ Core of the Contract: 'ALT-B4'... Sequential Milestone Payment Structure
The core of this contract is Alteogen's ALT-B4 technology. ALT-B4 is a proprietary technology utilizing human hyaluronidase, and under this contract, the technology will be transferred for application to the development and commercialization of multiple products.
The upfront payment, payable upon signing, is expected to be received within 30 days of the contract date. Thereafter, additional milestones will be triggered sequentially depending on development stages, commercialization progress, and whether the counterparty exercises its options.
The maximum contract value of $3.223 billion announced by the company is the sum of all milestones receivable through the development and commercialization of multiple products applying ALT-B4, while sales royalties generated from actual product sales will be set separately.
■ Full Receipt of the 4-Trillion-Won-Scale Amount Remains Uncertain
However, the 4-trillion-won-scale contract value is not guaranteed to be received in full. If clinical trials do not proceed as planned or development is discontinued, some milestones may not be received, and if product sales fall short of expectations after commercialization, actual receipts could be lower than the maximum contract amount.
The won conversion was calculated using the exchange rate of 1,370.30 won per dollar, the official rate at the Seoul Foreign Exchange Market on September 2, 2026, making the maximum contract value of $3.223 billion approximately 4.4165 trillion won.
■ Option Exercises and Development Speed Are Key Variables
As this contract is structured to allow ALT-B4 to be applied to multiple products rather than being limited to a single product, future option exercises and the expansion of the development pipeline are expected to play a crucial role. Rather than the contract size itself, which products ALT-B4 is applied to and how quickly clinical and approval stages progress will likely be the key variables determining the scale of future milestone receipts.
Meanwhile, both the date of occurrence and the contract signing date disclosed by the company are based on Korean time.
[This article is for informational purposes, written based on publicly available market information and materials, and does not recommend the purchase, sale, or holding of any specific stock. Stock investments may result in principal loss, and the final investment decision and responsibility rest with the investor. This article was written with AI assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.

![[Breaking] Evernous Holdings (XRPN) Surges 6.91% to $8.51... XRP-Related Stocks Draw Intraday Attention](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F625891%2Fdbdb0763d6fb4568%2Fvariants%2Fhero.webp&w=1920&q=75)

